当前位置: X-MOL 学术Expert Opin. Biol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Preclinical studies of chimeric antigen receptor-modified natural killer cells in cancer immunotherapy: a review
Expert Opinion on Biological Therapy ( IF 3.6 ) Pub Date : 2021-10-22 , DOI: 10.1080/14712598.2021.1983539
Mina Hosseini 1, 2 , Zahra Habibi 3 , Narges Hosseini 4 , Sina Abdoli 3 , Nima Rezaei 1, 5, 6
Affiliation  

ABSTRACT

Introduction

As one of the most efficacious methods of cancer immunotherapy, chimeric antigen receptor-modified immune cells have recently drawn enormous attention. After the great success achieved with CAR-T-cells in cancer treatment both in preclinical setting and in the clinic, other types of immune cells, including natural killer (NK)-cells and macrophages, have been evaluated for their anti-cancer effects along with their potential superiority against CAR-T-cells, especially in terms of safety. First introduced by Tran et al. almost 26 years ago, CAR-NK-cells are now being considered as efficient immunotherapeutic modalities in various types of cancers, not only in preclinical setting but also in numerous phase I and II clinical studies.

Areas Covered

In this review, we aim to provide a comprehensive survey of the preclinical studies on CAR-NK-cells’ development, with an evolutional approach on CAR structures and their associated signaling moieties. Current NK-cell sources and modes of gene transfer are also reviewed.

Expert Opinion

CAR-NK-cells have appeared as safe and effective immunotherapeutic tools in preclinical settings; however, designing CAR structures with an eye on their specific biology, along with choosing the optimal cell source and gene transfer method require further investigation to support clinical studies.



中文翻译:

嵌合抗原受体修饰的自然杀伤细胞在癌症免疫治疗中的临床前研究:综述

摘要

介绍

作为最有效的癌症免疫治疗方法之一,嵌合抗原受体修饰的免疫细胞最近引起了极大的关注。在 CAR-T 细胞在临床前和临床中的癌症治疗中取得巨大成功之后,其他类型的免疫细胞,包括自然杀伤 (NK) 细胞和巨噬细胞,也被评估了它们的抗癌作用。与 CAR-T 细胞相比具有潜在优势,尤其是在安全性方面。由Tran 等人首先介绍。大约 26 年前,CAR-NK 细胞现在被认为是各种癌症的有效免疫治疗方式,不仅在临床前环境中,而且在众多 I 期和 II 期临床研究中。

涵盖的领域

在这篇综述中,我们的目标是对 CAR-NK 细胞发育的临床前研究进行全面调查,并提供关于 CAR 结构及其相关信号部分的进化方法。还回顾了当前的 NK 细胞来源和基因转移模式。

专家意见

CAR-NK 细胞已在临床前环境中作为安全有效的免疫治疗工具出现;然而,设计 CAR 结构时着眼于其特定的生物学,以及选择最佳的细胞来源和基因转移方法,需要进一步调查以支持临床研究。

更新日期:2021-10-22
down
wechat
bug